Archive
Home / Media Centre / Archive
Here you can find the archive of all Press Releases prior to 2022
Filter by date:
Showing 1107 press releases before 2022
-
Brilinta reduced the risk of cardiovascular events in patients with coronary artery disease and type-2 diabetes in Phase III THEMIS trial
-
Detailed results from Phase III DAPA-HF trial showed Farxiga significantly reduced both the incidence of cardiovascular death and the worsening of heart failure
-
AstraZeneca to present data at ESC Congress 2019 that potentially redefine the treatment of heart failure
-
Anifrolumab Phase III trial meets primary endpoint in systemic lupus erythematosus
-
Fasenra granted US Orphan Drug Designation for eosinophilic oesophagitis
-
Breztri Aerosphere Phase III ETHOS trial met its primary endpoint in chronic obstructive pulmonary disease
-
FDA grants Fast Track designation for Farxiga in chronic kidney disease
-
Roxadustat approved in China for the treatment of anaemia in non-dialysis-dependent patients with chronic kidney disease
-
AstraZeneca agrees to buy US FDA Priority Review Voucher from Sobi
-
Update on the Phase III NEPTUNE trial of Imfinzi plus tremelimumab in Stage IV non-small cell lung cancer
Latest articles and press releases
All of our latest press releases and articles are available to explore
